Reaction Steps
Using general procedure E with 4-(4-{[1-(3-amino-1-methyl-propyl)-piperidin-4-yl]-benzyl-amino}-benzyl)-benzoic acid methyl ester (see EXAMPLE 100) (79 mg, 0.16 mmol) and 4,6-dimethyl-pyrimidine-5-carboxylic acid (30 mg, 0.20 mmol) followed by general procedure K with the resulting ester gave COMPOUND 102 as a yellow powder (59 mg, 70% over 2 steps). 1H NMR (CDCl3+CD3OD) δ 1.20 (d, 3H, J=6.0 Hz), 1.68 (m, 1H), 1.90 (m, 4H), 2.13 (m, 1H), 2.40 (s, 6H), 2.61 (m, 1H), 2.81 (m, 1H), 3.09-3.37 (m, 4H), 3.54 (m, 1H), 3.80 (m, 3H), 4.23 (s, 2H), 6.55 (d, 2H, J=7.8 Hz), 6.90 (d, 2H, J=7.8 Hz), 7.09 (m, 7H), 7.71 (d, 2H, J=7.5 Hz), 8.77 (s, 1H). 1H NMR (CDCl3+CD3OD) δ 12.71, 21.99, 27.18, 27.54, 31.62, 37.35, 41.10, 45.34, 50.14, 51.13, 54.40, 58.93, 114.26, 126.48, 126.91, 128.73, 128.87, 129.96, 130.02, 130.82, 131.69, 140.33, 146.24, 147.43, 157.34, 163.70, 167.59, 172.17. ES-MS m/z 606 (M+H). Anal. Calcd. for C37H43N5O3.0.7CH2Cl2: C, 68.07; H, 6.73; N, 10.53. Found. C, 68.09; H, 6.66; N, 10.49.
